Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.77 |
| ▸ | PPARG | P37231 | 5/20 | 0.77 |
| ▸ | PPARA | Q07869 | 3/20 | 0.60 |
| ▸ | PPARD | Q03181 | 1/20 | 0.60 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17554117 | 0.83 | ABCG2 (0.63) | NR1H4PPARGPPARAPPARDMAPT | |
| SCHEMBL30560465 | 0.83 | ABCG2 (0.63) | NR1H4PPARGPPARAPPARDMAPT | |
| SCHEMBL24133347 | 0.82 | NR1H4 (0.74) | NR1H4PPARGPPARAPPARDSLC16A3 | |
| SCHEMBL30560536 | 0.81 | NR1H4 (0.55) | NR1H4PPARGMAPTHTTKDM4E | |
| SCHEMBL17554014 | 0.81 | NR1H4 (0.55) | NR1H4PPARGMAPTHTTKDM4E | |
| SCHEMBL17554087 | 0.81 | PPARG (0.76) | NR1H4PPARGSLC16A3MAPTHTT | |
| SCHEMBL17554096 | 0.79 | NR1H4 (0.67) | NR1H4PPARGMAPTKDM4ENPC1 | |
| SCHEMBL21870109 | 0.79 | NPC1 (0.51) | NR1H4PPARGMAPTHTTKDM4E | |
| SCHEMBL24133370 | 0.79 | NR1H4 (0.66) | NR1H4PPARGPPARAPPARDSLC16A3 | |
| SCHEMBL5750887 | 0.79 | BACE1 (0.63) | NR1H4PPARGPPARAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628374-B1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-08-30 | — | — | EP | disclosed |
| EP-3628374-B1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-08-30 | — | — | EP | disclosed |
| EP-3628374-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2020-04-01 | — | — | EP | disclosed |
| EP-3628374-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2020-04-01 | — | — | EP | disclosed |
| US-20190248756-A1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-08-15 | — | — | US | disclosed |
| US-20190248756-A1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-08-15 | — | — | US | disclosed |
| US-10273218-B2 | BCL-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10273218-B2 | BCL-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| EP-3174602-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016728-A2 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248756-A1 | BCL-3 INHIBITORS | BCL3, BCL2, BCL2L13 | NR1H4 2479/4885PPARG 3081/4885PPARA 4470/4885 |
| US-10273218-B2 | BCL-3 inhibitors | BCL3, BCL2, BCL2L13 | NR1H4 2842/4885PPARG 2993/4885PPARA 4433/4885 |
| US-20170267653-A1 | BCL-3 INHIBITORS | BCL3, BCL2, BCL2L13 | NR1H4 2842/4885PPARG 2993/4885PPARA 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.